{"schemaVersion":1,"research":true,"symbol":"nvo","name":"Novo Nordisk","topic":"moat","path":"/stock/nvo/moat","status":"published","version":5,"updatedAt":"2026-10-19T13:05:31.401Z","locked":false,"publicFairValue":false,"fairValue":null,"moat":{"verdict":"narrow","summary":"Novo Nordisk retains a narrow, eroding moat from patented, approved medicines with demonstrated demand and successful product extensions. Wegovy pill uptake and broader launches strengthen evidence of commercial renewal, but 2025 share losses, continued realized price declines and 2026 gross-margin compression show material erosion. Manufacturing capability supports delivery without establishing a relative cost advantage. Remaining patents support finite protection, not guaranteed durability or strong pricing power.","advantages":[{"mechanism":"intangible_assets","claim":"Patents and marketed therapeutic franchises provide a current barrier to direct replication. Multi-year Wegovy growth, prescription uptake for its oral formulation and approvals for additional formulations demonstrate commercialization beyond a prospective pipeline.","durability":"The 2025 patent table lists principal semaglutide products through 2032 in the US and 2031 in Japan and Europe, but 2026 in China. Other patents may extend protection, although their effectiveness is unproven here. Renewal is demonstrated commercially, but long-term resistance to substitution remains mixed.","risks":"Actual GLP-1 volume-share losses, lower realized prices, generic patent challenges and geographically uneven exclusivity weaken protection. Pipeline failures and impairments constrain confidence in replacement products. Strong prescription starts do not establish patient persistence or superior economics.","invalidation":"The narrow-moat thesis would fail if generic entry or competing treatments caused sustained declines in underlying franchise volumes and sales despite new formulations, or if successful patent challenges removed protection in major markets before replacement products established meaningful demand. Persistent price and gross-profit deterioration despite volume growth would further invalidate economic protection.","competitors":["Cipla"],"evidenceIds":["e1","e2","e3","e4","e5","e6"],"counterEvidenceIds":["e7","e8","e9","e10","e11","e12","e13"]}],"evidence":[{"id":"e1","sourceId":"filing-4","location":"2025 Annual Report, patent status table","excerpt":"•Mixtard® 50, biphasic human insulin\nOBESITY&\nWegovy® injection\n2032\n2026\n2031\n2031\nWegovy® pill \n2032\n2026\n2031\n2031\nSaxenda®\nExpired\nExpired\nExpired\nExpired\nDIABETES&\nOzempic®\n2032\n2026\n2031\n2031\nRybelsus®\n2032\n2026\n2031\n2031\nTresiba®\n2029\nExpired\n2027\n2028\nXultophy®\n2029\nExpired\nExpired\n2028\nRyzodeg®\n2029\nExpired\nExpired\n2028\nVictoza®\nExpired\nExpired\nExpired\nExpired\nHuman insulin and Modern insulins3\nExpired\nExpired\nExpired\nExpired\nRARE DISEASE\nNovoSeven®\nExpired\nExpired\nExpired\nExpired\nNorditropin®\nExpired\nExpired\nExpired\nExpired\n1."},{"id":"e2","sourceId":"filing-1","location":"Item 4, 2025 Wegovy commercial performance","excerpt":"In its fifth year after launch, revenue for the GLP-1 product Wegovy®, grew 36%, to DKK 79 billion."},{"id":"e3","sourceId":"filing-2","location":"Item 4, 2024 Wegovy commercial performance","excerpt":"In its fourth year after launch the GLP-1 product, Wegovy® revenue, grew 86% to DKK 58 billion."},{"id":"e4","sourceId":"filing-7","location":"H1 2026 strategic milestones, Wegovy pill prescriptions","excerpt":"–including more than 265,000 weekly TRx for Wegovy® pill, with best-in-class GLP-1 volume launch and now more than 5 million TRx since launch."},{"id":"e5","sourceId":"filing-7","location":"H1 2026 regulatory and clinical milestones","excerpt":"–Wegovy® pill approved in the UAE and the UK in June and in the EU in July\nDiabetes&:\n–UBT251 phase 2 trial in China successfully completed\n–Awiqli® approved in the US\n–The ZEUS phase 3 trial with ziltivekimab did not meet the primary endpoint\nRare Disease:\n–Etavopivat HIBISCUS phase 3 trial completed, successfully meeting both co-primary endpoints\n–Alhemo® paediatric US submission\n–Sogroya® positive opinion achieved in the EU and approved in Japan for non-replacement indications"},{"id":"e6","sourceId":"filing-7","location":"Q2 2026 commercial highlights, higher-dose launches","excerpt":"•Wegovy® HD was launched in the US in April, and Wegovy® 7.2 mg single-dose pen in the UK in June."},{"id":"e7","sourceId":"filing-1","location":"Item 4, realized 2025 GLP-1 volume-share losses","excerpt":"However, due to increased competition in both US and ex-US markets, Novo Nordisk has lost volume market share in the GLP-1 market places for both obesity and diabetes."},{"id":"e8","sourceId":"filing-7","location":"Q2 2026 adjusted sales, volume and realized pricing","excerpt":"Q2 2026 adjusted sales increased by 7% at CER to DKK 78,488 million, driven by GLP-1 volume growth in both operating units, partly offset by lower realised prices."},{"id":"e9","sourceId":"filing-7","location":"Legal matters, Cipla Ozempic generic application","excerpt":"Ozempic® ANDA Patent Litigation\nCipla notified Novo Nordisk that they have filed an ANDA with the FDA for a generic version of Ozempic®."},{"id":"e10","sourceId":"filing-7","location":"Legal matters, proposed entry before listed patent expiration","excerpt":"The ANDA contains Paragraph IV certifications to obtain approval to engage in the commercial manufacture, use, or sale of such products before the expiration of the patents currently listed for Ozempic® in the Orange Book."},{"id":"e11","sourceId":"filing-7","location":"Q2 2026 adjusted gross-margin comparison","excerpt":"Adjusted gross margin was realised at 78.2%, compared with 82.7% in Q2 2025."},{"id":"e12","sourceId":"filing-7","location":"Q2 2026 gross-margin decline, pricing and capacity agreement costs","excerpt":"The decline in gross margin is impacted by lower realised prices, one-time costs of around DKK 3 billion related to right-sizing of manufacturing capacity agreements, as well as a negative currency impact."},{"id":"e13","sourceId":"filing-7","location":"Q2 2026 reported operating profit and pipeline impairments","excerpt":"•Q2 2026 reported operating profit decreased by 16% at CER, with growth negatively impacted by the US 340B rebate provision reversal in Q2 2025 as well as non-cash impairment charges of DKK 6.3 billion in Q2 2026 related to intangible pipeline assets, including monlunabant (DKK 4.0 billion)."},{"id":"e14","sourceId":"filing-1","location":"Item 5, payer purchasing control and rebates","excerpt":"US payers continue to leverage their size and control to demand higher rebates, particularly in the insulin segment, but increasingly in the GLP-1 category, as well."},{"id":"e15","sourceId":"filing-1","location":"Item 5, realized 2025 US net-price decline","excerpt":"As a result, average prices after rebates for the Novo Nordisk portfolio in 2025 in the United States declined."},{"id":"e16","sourceId":"filing-2","location":"Item 5, realized 2024 US net-price decline","excerpt":"As a result, average prices after rebates for the Novo Nordisk portfolio in 2024 in the United States declined."},{"id":"e17","sourceId":"filing-6","location":"2023 Annual Report, US portfolio net-price changes","excerpt":"In 2023, the average net price of both the US product portfolio and the US insulin portfolio decreased by 8.2% and 24.4%, respectively, compared to 10.5% and 19.5% in 2022, as a result of enhancements to secure formulary access for insured patients, as well as the evolution of channel and payer mix."},{"id":"e18","sourceId":"filing-7","location":"Q2 2026 International Operations, realized China price reductions","excerpt":"The lower Wegovy® prices were mainly realised in Region China, following list price reductions in late Q4 2025."},{"id":"e19","sourceId":"filing-8","location":"Q1 2026 commercial discussion, announced January 2027 list-price reductions","excerpt":"During the quarter, Novo Nordisk announced that, effective 1 January, 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy® (semaglutide) injection 2.4 mg, injection 7.2 mg and tablets up to 25 mg, Ozempic® (semaglutide) injection 0.5 mg, 1 mg, and 2 mg, and Ozempic pill® (semaglutide) tablets 7 mg or 14 mg to USD 675, representing reductions from the current list price of approximately 50% and 35% for Wegovy® and Ozempic®, respectively."},{"id":"e20","sourceId":"filing-7","location":"H1 2026 reported and adjusted profit reconciliation","excerpt":"Strategic milestones\nPerformance highlights\nCommercial execution\nFinancials\nCash flow and capital allocation\nOutlook\nR&D pipeline progress\nSustainability\nCorporate Governance\nLegal matters\nFinancial information\n Company announcement No 48 / 2026\nFinancial report for the period 1 January 2026 to 30 June 2026\nPage 13 of 37\nH1 2026 DEVELOPMENT IN COSTS AND OPERATING PROFIT\nH1 2026 PROFIT AND LOSS\nDKK million\nReported\n340B provision reversal\nMajor impairments\nMajor legal matters\nAdjusted\nGrowth\nin DKK\nGrowth\nat CER\nNet sales\n175,311\n(26,760)\n—\n—\n148,551\n(2\n%)\n2\n%\nCost of goods sold\n(30,698)\n(30,698)\n19\n%\n19\n%\nGross profit\n144,613\n(26,760)\n—\n—\n117,853\n(7\n%)\n(2\n%)\nGross margin\n82.5%\n79.3%\nSales and distribution costs\n(27,074)\n(27,074)\n(17\n%)\n(13\n%)\nPercentage of sales\n15.4%\n18.2%\nResearch and development costs\n(28,071)\n6,328\n(21,743)\n(1\n%)\n1\n%\nPercentage of sales\n16.0%\n14.6%\nAdministrative costs\n(2,449)\n(2,449)\n(3\n%)\n(1\n%)\nPercentage of sales\n1.4%\n1.6%\nOther operating income and expenses\n(340)\n(340)\nN/A\nN/A\nOperating profit (EBIT)\n86,679\n(26,760)\n6,328\n—\n66,247\n(5\n%)\n2\n%\nOperating margin\n49.4%\n44.6%\nTo enhance transparency and comparability of underlying operating performance, the below commentary of development in costs and operating profit excludes certain exceptional and non-recurring effects, primarily of non-cash nature, and growth rates are in CER, unless otherwise noted."},{"id":"e21","sourceId":"filing-7","location":"Q2 2026 gross-margin offsets from productivity and product mix","excerpt":"This was partly countered by productivity gains and a positive product mix from increased GLP-1 sales."},{"id":"e22","sourceId":"filing-7","location":"Q2 2026 sales and distribution cost savings","excerpt":"The decrease is driven by savings across regions following the company-wide restructuring announced in Q3 2025 as well as quarter-to-quarter variability in spending."},{"id":"e23","sourceId":"filing-7","location":"Legal matters, Supreme Court denial of pricing-law challenge","excerpt":"Strategic milestones\nPerformance highlights\nCommercial execution\nFinancials\nCash flow and capital allocation\nOutlook\nR&D pipeline progress\nSustainability\nCorporate Governance\nLegal matters\nFinancial information\n Company announcement No 48 / 2026\nFinancial report for the period 1 January 2026 to 30 June 2026\nPage 23 of 37\nLEGAL MATTERS\nInflation Reduction Act Litigation\nOn 18 May 2026, the United States Supreme Court denied Novo Nordisk’s Petition for certiorari seeking review of the Third Circuit’s decision affirming the dismissal of Novo Nordisk’s lawsuit challenging the legality of the pricing provisions of the Inflation Reduction Act."},{"id":"e24","sourceId":"filing-7","location":"H1 2026 cash flow and capital allocation, free cash flow","excerpt":"Free cash flow in the first six months of 2026 was DKK 55.3 billion compared to DKK 38.4 billion in 2025."},{"id":"e25","sourceId":"filing-7","location":"H1 2026 cash-flow timing and expenditure drivers","excerpt":"The increase in free cash flow is driven by phasing of operating expenses, timing of US rebate payments and tax payments, as well as lower capital expenditure, in line with guidance provided for full-year 2026."},{"id":"e26","sourceId":"filing-7","location":"H1 2026 actual property, plant and equipment expenditure","excerpt":"Capital expenditure for property, plant and equipment was DKK 24.0 billion compared with DKK 28.1 billion in 2025, primarily reflecting investments in additional capacity for active pharmaceutical ingredient (API) production and fill-finish capacity for both current and future injectable and oral products."},{"id":"e27","sourceId":"filing-7","location":"H1 2026 actual shareholder distributions","excerpt":"Novo Nordisk returned DKK 41.2 billion to shareholders via share buybacks (DKK 5.9 billion) and dividends (DKK 35.3 billion) in the first six months of 2026."},{"id":"e28","sourceId":"filing-2","location":"Item 4, acquisition price and debt financing","excerpt":"The purchase price of the three sites totalled USD 11.7 billion, which was mainly debt-financed."},{"id":"e29","sourceId":"filing-5","location":"Share-based payment note, existing management LTIP programmes","excerpt":"Long-term share-based incentive programme\nManagement Board\nThe LTIPs commenced in 2022, 2023 and 2024 have a three-year performance"},{"id":"e30","sourceId":"filing-5","location":"Share-based payment note, employment and holding conditions","excerpt":"period, subject to continued employment, and a subsequent two-year holding"},{"id":"e31","sourceId":"filing-5","location":"Share-based payment note, target setting and allocation thresholds","excerpt":"period. Targets are set at the beginning of the performance period and include determination of threshold, on-target level of performance and level of performance to achieve maximum allocation of shares."},{"id":"e32","sourceId":"filing-5","location":"Share-based payment note, financial and non-financial performance targets","excerpt":"For 2024 onward, the Board sets both financial and non-financial targets for a three-year period which are linked to three-year average growth in sales, operating profit and non-financial performance."},{"id":"e33","sourceId":"filing-4","location":"2025 share-based payment note, expected shares vesting","excerpt":"On 31 December 2025, a total of 8.8 million shares (13.3 million in 2024 and 18.9"},{"id":"e34","sourceId":"filing-1","location":"Item 6, separate board and executive membership","excerpt":"The Board of Directors and Executive Management are separate bodies and have no overlapping members."},{"id":"e35","sourceId":"filing-1","location":"Item 6, Audit Committee oversight responsibilities","excerpt":"The Audit Committee The Audit Committee mainly assists the Board of Directors with the oversight of: external auditors; the internal audit function; handling complaints reported through the Compliance Hotline (the Company's whistleblower complaint system); financial and sustainability reporting (environmental, social and governance); enterprise risk management system and the operational risk profile of the Company; financial counterpart exposure; internal controls over financial and ESG reporting; business ethics compliance; information security; insurance coverage and special theme reviews."},{"id":"e36","sourceId":"filing-1","location":"Major shareholders, ownership and voting rights as of 3 February 2026","excerpt":"However, set forth below is information as of 3 February 2026 with respect to (a) any shareholder who is known to the Company to be the owner 22 Novo Nordisk Form 20-F 2025 ITEM 8 FINANCIAL INFORMATION of more than 5% of any class of Novo Nordisk A/S' securities and (b) the total amount of any class owned by Novo Nordisk A/S and its subsidiaries (treasury shares) and by the Board of Directors and executives as a group: Title of class Identity of person or group Shares owned Percent of class Percent of total votes A shares Novo Holdings A/S 1,074,872,000 100.00 76.02 B shares Novo Holdings A/S 177,560,500 5.24 1.26 B shares Novo Nordisk A/S and subsidiaries (treasury shares) 21,375,280 * 0.63 0.15 B shares Board of Directors and executives 1,173,813 0.03 0.01 *) Treasury shares are included, however, voting rights of treasury shares cannot be exercised."},{"id":"e37","sourceId":"filing-1","location":"Item 16G, People & Governance Committee independence","excerpt":"Under the Danish Corporate Governance Recommendations, less than half of the members of the People & Governance Committee are considered independent, as opposed to the majority as recommended."},{"id":"e38","sourceId":"filing-1","location":"Item 4, realized 2025 supply improvement","excerpt":"However, the supply situation across products has improved throughout 2025 due to continued scaling of manufacturing capabilities."},{"id":"e39","sourceId":"filing-7","location":"Q2 2026 commercial highlights, US branded obesity new-patient starts","excerpt":"Measured by new patient starts, the Wegovy® franchise remains the market leader among branded obesity medications in the US."},{"id":"e40","sourceId":"filing-7","location":"H1 2026 financial highlights and exceptional 340B adjustments","excerpt":"Strategic milestones\nPerformance highlights\nCommercial execution\nFinancials\nCash flow and capital allocation\nOutlook\nR&D pipeline progress\nSustainability\nCorporate Governance\nLegal matters\nFinancial information\n Company announcement No 48 / 2026\nFinancial report for the period 1 January 2026 to 30 June 2026\nPage 3 of 37\nPERFORMANCE HIGHLIGHTS\nFINANCIAL HIGHLIGHTS\nQ2 2026\nGrowth\nin DKK\nGrowth\nat CER\nH1 2026\nGrowth\nin DKK\nGrowth\nat CER\n(Amounts are in DKK million, except for earnings per share)\nNet sales\n78,488\n2%\n3\n%\n175,311\n13%\n18\n%\nAdjusted net sales1\n78,488\n6%\n7\n%\n148,551\n(2%)\n2\n%\nAdjusted sales per therapy area\nTotal Obesity care\n23,152\n15%\n16%\n44,064\n14%\n19%\nTotal Diabetes care\n50,429\n2%\n3%\n95,365\n(9%)\n(5%)\nObesity and Diabetes care total\n73,581\n6%\n7%\n139,429\n(2%)\n2%\nRare disease total\n4,907\n2%\n6%\n9,122\n(3%)\n2%\nAdjusted sales for key brands:\nWegovy® injectable\n19,484\n1%\n1%\n37,719\n3%\n7%\nWegovy® pill\n3,218\nN/A\nN/A\n5,474\nN/A\nN/A\nOzempic®\n31,375\n3%\n5%\n59,200\n(6%)\n(2%)\nOzempic®pill / Rybelsus®\n5,228\n(7%)\n(4%)\n9,800\n(13%)\n(9%)\nGross profit\n61,388\n(4%)\n(2\n%)\n144,613\n12%\n17\n%\nGross margin\n78.2%\n82.5%\nOperating profit (EBIT)\n27,061\n(19%)\n(16\n%)\n86,679\n20%\n27\n%\nOperating margin\n34.5%\n49.4%\nAdjusted gross profit1\n61,388\n0%\n2\n%\n117,853\n(7%)\n(2\n%)\nAdjusted gross margin\n78.2%\n79.3%\nAdjusted operating profit (EBIT)1\n33,389\n8%\n11\n%\n66,247\n(5%)\n2\n%\nAdjusted operating margin\n175,311 \n13\n%\n18\n%\nQ2 AND H1 2026 ADJUSTED SALES\nTo enhance transparency and comparability of underlying sales performance, the sections below exclude the exceptional and non-recurring reversals of sales rebate provisions related to the US 340B Drug Pricing Program of DKK 26.8 billion in Q1 2026 and DKK 2.6 billion in Q2 2025."},{"id":"e41","sourceId":"filing-7","location":"R&D pipeline progress, ZEUS primary endpoint","excerpt":"The trial did not meet its primary endpoint."},{"id":"e42","sourceId":"filing-1","location":"Item 4, realized Victoza sales decline","excerpt":"The total sales of Victoza® were DKK 3,020 million in 2025 (DKK 5,482 million in 2024)."},{"id":"e43","sourceId":"filing-1","location":"Item 4, licensed Victoza generic launch date","excerpt":"Consequently, these manufacturers were licensed to launch a generic version of Victoza® as of June 22, 2024."}],"changes":["Retain the narrow, eroding moat verdict; 2026 pill uptake and formulation launches strengthen demonstrated renewal without establishing a durable reversal of competitive pressure.","Replace the previous incomplete-exclusivity discussion with the supplied product-level patent table, including 2026 China and 2031–2032 principal-market semaglutide expirations.","Extend adverse pricing evidence into 2026, including realized China reductions. January 2027 US list-price cuts remain announced future actions.","Retain a mixed margin-resilience grade using current interim evidence: gross-margin compression is offset partly by productivity and spending savings. The exceptional 340B reversal is excluded when assessing underlying growth.","Reassess capital discipline using H1 2026 cash generation, distributions and capital expenditure alongside actual pipeline impairments and manufacturing agreement costs.","Retain incentive-alignment and governance grades only on current-catalog programme and governance disclosures; expected vesting is not treated as completed vesting."],"limitations":["All substantive evidence is issuer disclosure. Reported operating achievements support assessment, but leadership and comparative launch claims are not independently verified.","All supplied source dates have dateKind filed. The latest supplied filing is dated 4 August 2026; no later developments are established.","Cipla is explicitly identified as a generic challenger. Other named pharmaceutical companies occur in employment histories, litigation or collaboration passages that do not establish comparative competitive coverage.","No relative manufacturing-cost data, network effects, efficient-scale protection or demonstrated patient switching costs are supplied.","Prescription totals, patient reach and sales provide indirect demand evidence, not patient-level retention rates. Early launches may include wholesaler stocking, and prescription capture is acknowledged as incomplete.","Patent dates do not guarantee enforceability or commercial exclusivity. Pipeline candidates and forecast access initiatives remain potential advantages.","Detailed individual executive holdings, realized incentive payouts and current target calibration are absent. Aggregate insider ownership and existing programme conditions do not prove exceptional alignment.","Adjusted measures exclude significant items and require reconciliation. H1 2026 free-cash-flow comparisons use a revised definition, and timing effects limit extrapolation."],"qualityAssessments":[{"category":"moat","checks":[{"criterion":"structural_advantage","grade":2,"rationale":"Principal-product patents and commercially successful formulations establish a current intangible-asset barrier. Realized share losses limit the strength of differentiation; manufacturing scale does not establish lower relative costs.","evidenceIds":["e1","e2","e4","e7","e38"]},{"criterion":"durability","grade":2,"rationale":"Patent protection into 2031–2032 in major markets and multi-year Wegovy demand support persistence. China expiry in 2026, generic challenges and actual legacy-product erosion make durability finite and mixed.","evidenceIds":["e1","e2","e3","e9","e10","e42","e43"]},{"criterion":"customer_dependency","grade":1,"rationale":"Prescription demand provides indirect evidence of therapeutic reliance, but dependence on Novo Nordisk specifically is fragile given share losses and payer bargaining control. Patient-level switching friction is not established.","evidenceIds":["e4","e7","e14"]},{"criterion":"erosion_resilience","grade":1,"rationale":"Pill uptake and new-patient-start leadership show a commercial response, but continued price declines and substantial gross-margin compression demonstrate fragile economic resilience. A sustained reversal of erosion is not established.","evidenceIds":["e4","e39","e7","e8","e11","e12"]}]},{"category":"pricing_power","checks":[{"criterion":"realized_pricing","grade":0,"rationale":"Direct adverse outcomes include US net-price declines in 2023–2025 and lower realized prices in Q2 2026, including China reductions. Announced 2027 US list-price cuts add prospective pressure but are not counted as realized outcomes.","evidenceIds":["e15","e16","e17","e8","e18","e19"]},{"criterion":"retention","grade":2,"rationale":"Assessed indirectly from multi-year Wegovy growth, ongoing prescriptions and 2026 volume growth. These support continuing demand, while share losses and H1 diabetes sales weakness are contrary evidence. No patient retention rate is inferred.","evidenceIds":["e2","e3","e4","e8","e7","e40"]},{"criterion":"margin_resilience","grade":2,"rationale":"Q2 adjusted gross margin fell from 82.7% to 78.2%, reflecting lower prices, manufacturing agreement costs and currency. Productivity and spending savings helped H1 adjusted operating profit grow 2% at CER alongside 2% adjusted sales growth. This is mixed resilience, with reported growth distorted by the exceptional 340B reversal.","evidenceIds":["e11","e12","e21","e22","e20","e40"]},{"criterion":"contractual_freedom","grade":1,"rationale":"Payer purchasing control demonstrably drives higher rebates, and the pricing-law challenge failed at the Supreme Court stage. Novo Nordisk can announce list-price changes, but disclosed outcomes show constrained effective pricing discretion. Detailed payer contract terms are missing.","evidenceIds":["e14","e15","e23","e19"]}]},{"category":"strong_management","checks":[{"criterion":"capital_discipline","grade":2,"rationale":"H1 2026 free cash flow of DKK 55.3 billion exceeded DKK 41.2 billion of distributions, with lower actual capital expenditure. Timing benefits limit extrapolation. The debt-financed USD 11.7 billion acquisition, pipeline impairments and manufacturing agreement right-sizing costs offset these positives; investment returns remain unproven.","evidenceIds":["e24","e25","e26","e27","e28","e13","e12"]},{"criterion":"incentive_alignment","grade":2,"rationale":"Existing LTIPs disclose three-year performance periods, continued-employment conditions, subsequent holding periods and financial and non-financial targets. The 2025 expected-vesting disclosure confirms ongoing programmes but does not prove actual vesting or effective payout calibration. Individual ownership and realized awards remain insufficiently disclosed.","evidenceIds":["e29","e30","e31","e32","e33"]},{"criterion":"execution","grade":2,"rationale":"Supply improvement, prescription uptake, formulation launches and approvals demonstrate delivery through operating outcomes. Share losses, pipeline impairments and the failed ZEUS endpoint make the overall record mixed. Results are not attributed entirely to the recently appointed CEO.","evidenceIds":["e38","e4","e5","e6","e7","e13","e41"]},{"criterion":"governance","grade":2,"rationale":"Separate board and executive membership and specified Audit Committee oversight establish substantive governance arrangements. Concentrated voting control and less-than-half independent People & Governance Committee membership constrain minority safeguards. These structures do not demonstrate exceptional oversight effectiveness.","evidenceIds":["e34","e35","e36","e37"]}]}],"financialAssessments":[],"qualityPolicy":"quality-scores-2","sourcePolicy":"issuer-evidence-4","basisHash":"6a444aa1e779d959017461972874b23c77407a4fa5444781e5f77dc36228b38a","updatedAt":"2026-10-19T13:05:31.401Z","sources":[{"id":"filing-1","url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm","publishedAt":"2026-02-04","sha256":"28126d08723509b9f9180877dd5c884200f394be1eda360409eedec520d6ce8c","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-2","url":"https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/nvo-20241231.htm","publishedAt":"2025-02-05","sha256":"0448279b953af1e8dcb5fd88386637475a61d656aabd20470564f44d7d3c513e","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-3","url":"https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/nvo-20231231.htm","publishedAt":"2024-01-31","sha256":"54bd5e6d3d65378307b4e580fa3e048583f45741102c66a695c28bf0398e406f","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-4","url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231_d2.htm","publishedAt":"2026-02-04","sha256":"f500ae6c51e2022513d97f39d3562a1b2ed9b58c11b4fdb14fbc0707cfece32d","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-5","url":"https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/nvo-20241231_d2.htm","publishedAt":"2025-02-05","sha256":"86040724bbc330380e4ff8d63b67605dc6194fa81ca0d363c3c185482bab491c","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-6","url":"https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/nvo-20231231_d2.htm","publishedAt":"2024-01-31","sha256":"69197498110e2ce78c73ae1ea7ebe067215b9946738fea3285d80c1cdd52ca01","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-7","url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm","publishedAt":"2026-08-04","sha256":"03199bb73b0c08267a9b0eb50b802fa8f19814ba41c259342ffdab2c5fdf8810","citationPolicy":"numeric-lines-1","dateKind":"filed"},{"id":"filing-8","url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000018/caq12026.htm","publishedAt":"2026-05-06","sha256":"f78a5da53ef3e3ebfe454da34dd88e9fa6dd37adfcea8191245a5bbd47a7b89e","citationPolicy":"numeric-lines-1","dateKind":"filed"}],"model":"gpt-6.1-sol","providerId":"codex:b4bb93da48bcc95a0328340ab88584e58d259a734ea38c805fa5e90cfe77957b","usage":{"input_tokens":111353,"cached_input_tokens":0,"cache_write_input_tokens":0,"output_tokens":4436,"reasoning_output_tokens":89}},"signals":[{"period":"2021","end":"2021-12-31","values":{"gross_margin":83.19744318181819,"operating_margin":41.65056818181818,"roic":64.00529511403596,"fcf_margin":34.56321022727273,"sbc_revenue":0.7386363636363636},"issues":{"pe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","peg":"Two complete TTM earnings bases and their diluted share counts are required for year-over-year growth.","pfcf_growth":"Two complete TTM FCF bases and their diluted share counts are required for year-over-year growth.","pb":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","earnings_yield":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","ev_ebitda":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","ebitda_margin":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%.","net_debt_ebitda":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","buybacks":"The reported inputs required for this metric are unavailable in the extracted statements for this period."}},{"period":"2022","end":"2022-12-31","values":{"gross_margin":83.92350554381365,"operating_margin":42.27595872373611,"roic":65.62916207040288,"fcf_margin":37.71658171050103,"sbc_revenue":0.8697175537145246},"issues":{"pe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","peg":"Two complete TTM earnings bases and their diluted share counts are required for year-over-year growth.","pb":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","earnings_yield":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","ev_ebitda":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","ebitda_margin":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%.","net_debt_ebitda":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","buybacks":"The reported inputs required for this metric are unavailable in the extracted statements for this period."}},{"period":"2023","end":"2023-12-31","values":{"gross_margin":84.60137517706373,"operating_margin":44.163247381178934,"roic":76.00293569791371,"fcf_margin":35.77957556369773,"sbc_revenue":0.9252521947292055},"issues":{"pe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","peg":"Two complete TTM earnings bases and their diluted share counts are required for year-over-year growth.","pb":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","earnings_yield":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","ev_ebitda":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","ebitda_margin":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%.","net_debt_ebitda":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","buybacks":"The reported inputs required for this metric are unavailable in the extracted statements for this period."}},{"period":"2024","end":"2024-12-31","values":{"gross_margin":84.66889116159268,"operating_margin":44.193413979883125,"roic":58.2627422912029,"fcf_margin":25.41433800615007,"sbc_revenue":0.7882149977789487},"issues":{"pe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","peg":"Two complete TTM earnings bases and their diluted share counts are required for year-over-year growth.","pfcf_growth":"TTM FCF per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","pb":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","earnings_yield":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","ev_ebitda":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","ebitda_margin":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%.","net_debt_ebitda":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","buybacks":"The reported inputs required for this metric are unavailable in the extracted statements for this period."}},{"period":"2025","end":"2025-12-31","values":{"gross_margin":80.97869696891259,"operating_margin":41.30471358682991,"roic":37.86102509575111,"fcf_margin":19.07760205006083,"sbc_revenue":0.46430512774053273},"issues":{"pe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","peg":"Two complete TTM earnings bases and their diluted share counts are required for year-over-year growth.","pfcf_growth":"TTM FCF per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","pb":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","earnings_yield":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","ev_ebitda":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","ebitda_margin":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%.","net_debt_ebitda":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","buybacks":"The reported inputs required for this metric are unavailable in the extracted statements for this period."}}],"sources":[{"id":"filing-1","url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm","publishedAt":"2026-02-04","sha256":"28126d08723509b9f9180877dd5c884200f394be1eda360409eedec520d6ce8c","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-2","url":"https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/nvo-20241231.htm","publishedAt":"2025-02-05","sha256":"0448279b953af1e8dcb5fd88386637475a61d656aabd20470564f44d7d3c513e","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-3","url":"https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/nvo-20231231.htm","publishedAt":"2024-01-31","sha256":"54bd5e6d3d65378307b4e580fa3e048583f45741102c66a695c28bf0398e406f","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-4","url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231_d2.htm","publishedAt":"2026-02-04","sha256":"f500ae6c51e2022513d97f39d3562a1b2ed9b58c11b4fdb14fbc0707cfece32d","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-5","url":"https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/nvo-20241231_d2.htm","publishedAt":"2025-02-05","sha256":"86040724bbc330380e4ff8d63b67605dc6194fa81ca0d363c3c185482bab491c","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-6","url":"https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/nvo-20231231_d2.htm","publishedAt":"2024-01-31","sha256":"69197498110e2ce78c73ae1ea7ebe067215b9946738fea3285d80c1cdd52ca01","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-7","url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm","publishedAt":"2026-08-04","sha256":"03199bb73b0c08267a9b0eb50b802fa8f19814ba41c259342ffdab2c5fdf8810","citationPolicy":"numeric-lines-1","dateKind":"filed"},{"id":"filing-8","url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000018/caq12026.htm","publishedAt":"2026-05-06","sha256":"f78a5da53ef3e3ebfe454da34dd88e9fa6dd37adfcea8191245a5bbd47a7b89e","citationPolicy":"numeric-lines-1","dateKind":"filed"}],"history":[{"version":5,"updatedAt":"2026-10-19T13:57:15.039Z","verdict":"narrow","value":null},{"version":4,"updatedAt":"2026-10-18T16:49:32.080Z","verdict":"narrow","value":null},{"version":3,"updatedAt":"2026-10-18T16:35:43.872Z","verdict":"narrow","value":null},{"version":2,"updatedAt":"2026-10-18T02:27:49.793Z","verdict":"narrow","value":null},{"version":1,"updatedAt":"2026-10-18T02:18:02.026Z","verdict":null,"value":null}],"hasRequested":false,"requestStatus":"completed","researchIssue":null,"archivedMoat":null,"scope":"supported_catalog"}